Efficacy and safety of lapatinib combined with chemotherapy for middle and advanced esophageal cancer
10.3760/cma.j.cn115355-20240621-00305
- VernacularTitle:拉帕替尼联合化疗治疗中晚期食管癌的效果及安全性
- Author:
Qian LIU
1
;
Lei WANG
;
Ye LU
;
Dandan ZHU
Author Information
1. 淮安市第五人民医院肿瘤内科，淮安 223300
- Publication Type:Journal Article
- Keywords:
Esophageal neoplasms;
Lapatinib;
Drug therapy, combined;
Treatment outcome
- From:
Cancer Research and Clinic
2025;37(8):618-622
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical efficacy and safety of lapatinib combined with chemotherapy for middle and advanced esophageal cancer.Methods:A retrospective cohort study was conducted. A total of 91 patients with middle and advanced esophageal cancer who received treatment in the Fifth People's Hospital of Huai'an from January 2022 to December 2022 were selected. According to the treatment method, all patients were divided into the control group (46 cases receiving carboplatin and albumin paclitaxel chemotherapy) and the observation group (45 cases receiving lapatinib based on chemotherapy regimen of the control group). The clinical efficacy, tumor marker levels, immune function indicators, quality of life, and adverse reactions between the 2 groups were compared.Results:There were no statistically significant differences in the baseline data between the control group and the observation group (all P > 0.05). The objective remission rate [66.67% (30/45) vs. 45.65% (21/46)] and the disease control rate [93.33% (42/45) vs. 76.09% (35/46)] of the observation group were higher than those of the control group, and the differences were statistically significant ( χ2 = 4.08, P = 0.043; χ2 = 5.20, P = 0.023). After treatment, tumor abnormal protein [(102±9) μm 2vs. (112±10) μm 2], cytokeratin 19 fragment 21-1 [(22.5±2.8) ng/ml vs. (24.2± 3.0) ng/ml], carbohydrate antigen 199 [(127±14) U/ml vs. (145±17) U/ml], tumor specific growth factor [(60±5) U/ml vs. (66±5) U/ml] levels and esophageal cancer patient supplementary scale score [(37±4) points vs. (40±4) points] in the observation group were lower than those in the control group, and the differences were statistically significant (all P < 0.05). After treatment, the observation group had a higher proportion of CD3 + cells [(71±6) % vs. (66±5)%)], CD4 +/CD8 + ratio (1.85±0.22 vs. 1.71±0.23), and Karnofsky functional status score [(88±6) points vs. (85±6) points] compared to those in the control group, and the differences were statistically significant (all P < 0.05). There was no statistically significant difference in the incidence of adverse reactions between the 2 groups [17.39% (8/46) vs. 26.67% (12/45), χ2 = 1.14, P = 0.285]. Conclusions:Lapatinib combined with carboplatin and albumin paclitaxel chemotherapy regimen for middle and advanced esophageal cancer can effectively improve efficacy and patients' quality of life by enhancing immune function and reducing tumor marker levels. Its medication safety can be ensured.
